BCL2 and acute lymphoblastic leukemia: Recent advances in genomic profiling of ALL have led to the discovery of up to 22 molecular subtypes of B-ALL3, many of which are defined by characteristic gene rearrangements, including ZNF384, DUX4, BCL2, PAX5, NUTM1, and HLF. An improved understanding of ALL genomic landscape also enables the identification of new therapeutic targets and the exploration of novel therapy.